Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 165

Related Citations for PubMed (Select 24353018)

1.

Switching from high doses of pure μ-opioid agonists to transdermal buprenorphine in patients with cancer: a feasibility study.

Lundorff L, Sjøgren P, Hansen OB, Jonsson T, Nielsen PR, Christrup L.

J Opioid Manag. 2013 Jul-Aug;9(4):255-62. doi: 10.5055/jom.2013.0166.

PMID:
24353018
2.

A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain.

Mitra F, Chowdhury S, Shelley M, Williams G.

Pain Med. 2013 Jan;14(1):75-83. doi: 10.1111/pme.12011.

PMID:
23320402
3.

Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study.

Mercadante S, Porzio G, Ferrera P, Aielli F, Verna L, Tirelli W, Villari P, Casuccio A.

Clin Ther. 2009 Oct;31(10):2134-8. doi: 10.1016/j.clinthera.2009.10.013.

PMID:
19922884
4.
6.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.

PMID:
18503626
7.

[Pain therapy in the elderly:7-day transdermal buprenorphine patch in clinical practice. Results of a non-interventional study].

Wahle K, Krings D, Schwenke K.

MMW Fortschr Med. 2013 Mar 21;155 Suppl 1:25-31. Review. German.

PMID:
23678668
9.

Equipotent doses to switch from high doses of opioids to transdermal buprenorphine.

Mercadante S, Casuccio A, Tirelli W, Giarratano A.

Support Care Cancer. 2009 Jun;17(6):715-8. doi: 10.1007/s00520-008-0546-6. Epub 2008 Dec 23.

PMID:
19104845
10.

Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine.

Kress HG.

Eur J Pain. 2009 Mar;13(3):219-30. doi: 10.1016/j.ejpain.2008.04.011. Epub 2008 Jun 24. Review.

PMID:
18567516
11.

Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine.

Daitch J, Frey ME, Silver D, Mitnick C, Daitch D, Pergolizzi J Jr.

Pain Physician. 2012 Jul;15(3 Suppl):ES59-66.

12.

Controlled-release oxycodone tablets after transdermal-based opioid therapy in patients with cancer and non-cancer pain.

Ravera E, Di Santo S, Bosco R, Arboscello C, Chiarlone R.

Aging Clin Exp Res. 2011 Oct-Dec;23(5-6):328-32.

PMID:
22526067
13.

[Transdermal buprenorphine for treatment of chronic tumor and non-tumor pain].

Likar R, Griessinger N, Sadjak A, Sittl R.

Wien Med Wochenschr. 2003;153(13-14):317-22. German.

PMID:
12924108
16.

Transdermal buprenorphine in non-oncological moderate-to-severe chronic pain.

Gatti A, Dauri M, Leonardis F, Longo G, Marinangeli F, Mammucari M, Sabato AF.

Clin Drug Investig. 2010;30 Suppl 2:31-8. doi: 10.2165/1158409-S0-000000000-00000.

PMID:
20670047
17.

Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.

Portenoy RK, Payne R, Coluzzi P, Raschko JW, Lyss A, Busch MA, Frigerio V, Ingham J, Loseth DB, Nordbrock E, Rhiner M.

Pain. 1999 Feb;79(2-3):303-12.

PMID:
10068176
19.

Is buprenorphine transdermal patch equally safe and effective in younger and elderly patients with osteoarthritis-related pain? Results of an age-group controlled study.

Karlsson J, Söderström A, Augustini BG, Berggren AC.

Curr Med Res Opin. 2014 Apr;30(4):575-87. doi: 10.1185/03007995.2013.873714. Epub 2013 Dec 23.

PMID:
24320787
20.

Buprenorphine 5, 10 and 20 μg/h transdermal patch: a review of its use in the management of chronic non-malignant pain.

Plosker GL.

Drugs. 2011 Dec 24;71(18):2491-509. doi: 10.2165/11208250-000000000-00000. Review.

PMID:
22141389
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk